Enrico Hausermann, the brand new president of Assogenerici, in a recent interview in Quotidiano Sanità took stock of the current Italian situation and plans for the future. The president declared himself satisfied for 2012 with regard to the generics market, even if it was a rather troubled year. Some observers would not have imagined that Hausermann would evaluate 2012 as a positive year but instead the new president underlined the importance of prescription by active ingredient which immediately gave a good boost to the whole sector of equivalents. Going back is not possible according to Hausermann, who assures that it would be an anti-historical position and in conflict with European regulation. When the journalist of Quotidiano Sanità asks Hausermann what he expects from 2013, the president of Assogenerics answers: “We hope to be able to confirm the positive effects of last year's regulation. As for any other news, in reality at the moment it is difficult to imagine what the policies of the next government could be, also considering the lack of clear electoral programs on healthcare in general and on the pharmaceutical sector in particular.
We certainly expect that the diffusion of generic medicines will continue to be promoted with a view to further and necessary cost containment. On the other hand, if in recent years the territorial pharmaceutical expenditure has been under control it was thanks to the reduced prices of equivalent drugs. For 2013 we also hope for a period of certainty and regulatory stability. In fact, changing the rules during construction creates a disturbance in the daily management of companies and makes any planning impossible”.
January 21, 2013 . Those who the Pharmacy
